期刊文献+

瑞舒伐他汀钙合用左旋氨氯地平对颈动脉粥样硬化及血管内皮功能的影响 被引量:8

Effects of combined use of rosuvastain and levamlodipine on carotid artherosclerosis and the function of vascular endothelium in essential hypertension patients
原文传递
导出
摘要 目的:观察左旋氨氯地平和瑞舒伐他汀钙的降压作用及对高血压患者颈动脉内膜-中膜厚度(IMT)及血管内皮功能的影响。方法:选择160例高血压伴动脉粥样硬化的患者,随机分为2组,实验组80例,服用苯磺酸左旋氨氯地平片2.5~5mg.d-1,瑞舒伐他汀钙10 mg,1次/晚。对照组80例,服用苯磺酸左旋氨氯地平片2.5~5 mg.d-1,疗程12个月,于治疗前后用彩色多普勒超声检测颈动脉内膜-中膜厚度,肱动脉内皮依赖性舒张功能,监测血压、血脂变化。结果:实验组治疗后血压下降较对照组显著,实验组治疗后颈动脉IMT较对照组显著减小(P<0.05),肱动脉内皮依赖性舒张功能显著改善(P<0.05)。结论:瑞舒伐他汀钙联合左旋氨氯地平能明显减轻颈动脉粥样硬化病变,可作为高血压并颈动脉粥样硬化的常规用药。 OBJECTIVE To study the effect of combined use of rosuvastain and levamlodipine on blood pressure, intimamedia thickness(IMT) and the function of vascular endothelium. METHODS 160 patients,with essential hypertension and carotid atherosclerosis,were divided randomly into 2 groups. 80 patients of test group were treated with levamlodipine 2. 5-5 mg·d-1 and rosuvastain 10 mg every night while levamlodipine 2. 5-5 mg·d-1 for 80 patients of control group for 12 months. Intimamedia thickness of carotid and brachial artery endothelium-dependent diastolic function were tested by color Doppler ultrasound before and after the therapy, the blood pressure and blood lipid were also monitored. RESULIS After the therapy,there were significant differences in blood pressure,IMT and brachial artery endothelium-dependent diastolic function between test group and control group. CONCLUSION levamlodipine could be the normal medication of carotid atherosclerosis for it can lower blood pressure greatly and improve atherosclerosis while combination with rosuvastain.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第23期1962-1964,共3页 Chinese Journal of Hospital Pharmacy
关键词 瑞舒伐他汀钙 高血压 动脉硬化 左旋氨氯地平 rosuvastain hypertension atherosclerosis levamlodipine
  • 相关文献

参考文献11

  • 1Karpe F, Boquist S, Tang R,et al. Remnant lipoproteins are re- lated to intimamedia thickness of the carotid artery independ- ently of LDL cholesterol and plasma triglycerides[J]. J Lipid Res, 21)(11 ;42:17-21.
  • 2Mumones MJ ,Nicholas hi3, Lyon CJ. lnsuhn resistance and the endothelium[J]. Curt Diab Rep, 2()( )5,5 ( 4 ) : 2462-253.
  • 3Celermaier DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of aterosclerosis[J]. Lancet, 1992,340:1111-1115.
  • 4Nicholis SJ. Rosuvastatin and progression of atheroscler- osis [J]. Exper Rev Cardiovasc Ther, 2/~/8,6 (7) : 925-933.
  • 5Nissen SE, Nicholis SJ, Sipaht I, et al. Effect of very high-in- tensity statin therapy on regression of coronary atherosclerosis the ASTEROID trial[J]. JAMA, 21106,25 (4) : 215-223.
  • 6Takayama T, Hiro T,Yamagishi M, et al. Effect of rosuvasta tin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese sub- jects (COSMOS) [J]. Circulation, 2009,73 ( 11 ) : 2110-2117.
  • 7Turgan N, Habif S, Kabaroglu CG,et al. Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lip- id peroxidation status and aortic histology in cholesterol fed rabbitsEJ]. Biomed Sei,2003,10(1 ) :65-72.
  • 8Franzoni F, Santoro G, Regoli F, et al. An in vitro study of the per oxyl and hydroxyl radical scaver~ging capacity of the calcium antago- nist flaillodipine[J]. B[omed Pharmacother, 2004,58:423-6.
  • 9王如兴,蒋文平.氨氯地平L-型钙通道阻滞作用以外的血管生物学特性[J].中国临床康复,2006,10(45):142-144. 被引量:24
  • 10Chou TC, Yang SP, Pei D. Amlodipine inhibits pro-inflammato ry cytokines and free radical producation and inducible nitric oxide synthase expression in lipopolysaccharide/interferon stimulated cultured vascular smooth muscle cells [J]. Jpn J Pharmacol, 2002,89: 157-163.

二级参考文献21

  • 1Ruilope LM.Long-term protection in at-risk hypertensive patients:a role for nifedipine GITS? Blood Press 2002;11:106-9
  • 2The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2002;288:2981-97
  • 3Pitt B,Byington RP,Furberg CD,et al.for the PREVENT Investigators.Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events.Circulation 2000;102:1503-10
  • 4Jorgensen B,Simonsen S,Endresen K,et al.Restenosis and clinical outcome in patients treated with amlodipine after angioplasty:results from the coronary angioplasty amlodipine restenosis study (CAPARES).J Am Coll Cardiol 2000;35:592-9
  • 5Dahlof B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Ann (ASCOTBPLA):a multicentre randomised controlled trial.Lancet 2005;366(9489):895-906
  • 6Zanchetti A,Bond MG,Hennig M,et al.on behalf of the ELSA investigators.Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis:principal results of the European Lacidipine Study on Atherosclerosis (ELSA),a randomized,double-blind,long-term trial.Circulation 2002;106:2422-7
  • 7Phillips JE,Mason RP.Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine:role of electrostatic interactions.Atherosclerosis 2003;168:239-44
  • 8Tulenko TN,Chen M,Mason PE,et al.Physical effects of cholesterol on arterial smooth muscle membranes:evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis.J Lipid Res 1998;39:947-56
  • 9Mason RP.Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine:review of the evidence.Atherosclerosis 2002;165:191-9
  • 10Boo YC,Hwang J,Sykes M,et al.Shear stress stimulates phosphorylation of eNOS at Ser635 by a protein kinase A-dependent mechanism.Am J Physiol Heart Circ Physiol 2002;283:H1819-H1828

共引文献23

同被引文献84

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:344
  • 2赵水平.降胆固醇防治心脑血管疾病的现状[J].中华内科杂志,2007,46(2):168-169. 被引量:16
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4John R. Crouse Ⅲ,Joel S. Raichlen,Ward A. Riley,Gregory W. Evans,Mike K. Palmer,Daniel H. O' Leary,Diederick E. Grobbee,Michiel L. Bots,李军(译).瑞舒伐他汀对存在亚临床动脉粥样硬化的低危人群颈动脉内膜中层厚度进展的影响——METEOR试验[J].美国医学会杂志(中文版),2007,26(4):208-216. 被引量:45
  • 5Undas A. Brummel Ziedins KE, Potaezek DP, et al. Atorvastatin and quinapril inhibit therapy[J].J Thromb Haemost, 2006,4(11 ) : 2397-2404.
  • 6罗远英,腾日添.那普利联用他汀药物治疗高血压远期疗效观察[J].中国现代医学杂志,2008,10(9):61-62.
  • 7苟连平,吕湛,秦俭,等.洛伐他汀对急性冠脉综合征患者外周血单核细胞ABCAl蛋白表达的影响[J].中华心血管病杂志,2008,6(1):8-10.
  • 8Venero CV, Thompson PD. Managing statin myopathy[J]. Endocrinol Metab Clin North Am,2009,38(1):121-135.
  • 9Va|ero- Mufioz M, Martin- Fernfindez B, Ballesteros S, et al. Rosuvastatin improves insulin sensitivity in overweight rats in- duced by high fat diet. Role of SIRT1 in adipose tissue [J]. Clin Investig Arterioscler, 2014, 26 (4) : 161 - 167.
  • 10Kim W0 Hong MJ, Woo JS, et al. Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension J]. Chonnam Med J, 2013, 49 (1), 31-37.

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部